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Background: ORTHO-1 is a European, multicentric, ﬁrst in human clinical trial to prove safety and
feasibility after surgical implantation of commercially available biphasic calcium phosphate bioceramic
granules associated during surgery with autologous mesenchymal stromal cells expanded from bone
marrow (BM-hMSC) under good manufacturing practices, in patients with long bone pseudarthrosis.
Methods: Twenty-eight patients with femur, tibia or humerus diaphyseal or metaphyso-diaphyseal non-
unions were recruited and surgically treated in France, Germany, Italy and Spain with 100 or 200 million
BM-hMSC/mL associated with 5e10 cc of bioceramic granules. Patients were followed up during one
year. The investigational advanced therapy medicinal product (ATMP) was expanded under the same
protocol in all four countries, and approved by each National Competent Authority. Findings: With safetyde Madrid, Hospital Uni-
y Traumatología, Hospital de
drid, Spain.;
, egomezb@salud.madrid.org
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Expanded autologous BM-hMSC
Non-union
Bone tissue engineeringPlease cite this article in press as: E. Gome
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multicentric, non-comparative trial, Biomatas primary end-point, no severe adverse event was reported as related to the BM-hMSC. With feasibility
as secondary end-point, the participating production centres manufactured the BM-hMSC as planned.
The ATMP combined to the bioceramic was surgically delivered to the non-unions, and 26/28 treated
patients were found radiologically healed at one year (3 out of 4 cortices with bone bridging). Inter-
pretation: Safety and feasibility were clinically proven for surgical implantation of expanded autologous
BM-hMSC with bioceramic. Funding: EU-FP7-HEALTH-2009, REBORNE Project (GA: 241876).
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-union occurs in 5%e20% of long-bone fractures that fail to
heal properly after more than six months, causing morbidity, pro-
longed hospitalization, and considerable resource consumption [1]
Non-union is frequently related to impairment of the biological
potential of the fracture and biological augmentation is often
required [1] The standard augmentation consists of autologous
bone grafting surgically obtained from the same patient at a
different location, most often from the iliac crest, and transplanted
into the reconstruction site [2] The bone autograft fulﬁls the bio-
logical requirements to locally enhance bone regeneration. It con-
tains extracellular matrix (osteoconduction), growth factors
(osteoinduction) and cells (responsible for osteogenesis), thus
allowing to ﬁll the defect and to regenerate the bone [3] However,
its remarkable drawbacks include the limited available amount
without causing weakness of the donor structure; the scarce
osteoprogenitors available in the harvested area, also depending on
the age; the problems to re-harvest autograft because of subse-
quent ﬁbrous tissue invasion; the associated patient complications
(persistent pain, infection, scar, painful gait deriving in abnormality
or limp) or even patient refusal to the procedure [4] Besides, the
conﬁrmed effectiveness of autograft to regenerate bone is moder-
ate, particularly in complex scenarios as non-unions, with a current
radiological success rate (in at least 3 views) of 74% and a combined
clinical criteria success rate of 85% [2] Competing technology is not
far from this success rate and OP-1 (BMP-7) recipients were found
to sustain a 62% radiological healing rate and a clinical success rate
of 81% [3] However, limited evidence and heterogenous method-
ology in the literature suggest that alternative solutions to enhance
healing through bone regeneration in complex settingsmay require
different approaches and further research [5] Culture-expanded
autologous MSCs associated with biomaterials fulﬁl the requisites
of osteogenesis and possibly osteoinduction (both related to cells),
as well as osteoconduction (through the biomaterial), and have
attracted signiﬁcant attention [1,6].
A large variety of biomaterials have been clinically used to
provide osteoconduction, although rarely tested in clinical trials.
Among these, synthetic biphasic calcium phosphate (BCP) bio-
ceramics composed of hydroxyapatite (HA) and beta-tricalcium
phosphate (b-TCP) are currently used in clinical scenarios. Bio-
materials approved for clinical use are better candidates for a
clinical trial in combination with an Advance Therapy Medicinal
Product (ATMP), such as expanded MSC. However, preclinical
studies on the association of the selected biomaterial and the cell
product under investigation are also required by regulatory
agencies before a clinical trial can be launched.
A biphasic material composed of HA/b-TCP in a ratio of 20/80 in
weight was chosen after it was implanted in critical size defects in
mice [7] It was more efﬁcient than equivalent macro and micro-
structure of different calcium phosphate bioceramics such as HA, b-
TCP, BCP 60/40, 76/24, 63/37 and 56/44 [7,8] for combination withz-Barrena, et al., Feasibility a
ed mesenchymal stromal ce
erials (2018), https://doi.org/MSC before implantation.
Under the EU-FP7 REBORNE project, the BCP was supplied by
Biomatlante (Vigneux de Bretagne, France) under the name of
MBCPþ™ (Reference 1502MþG05), which is CEmarkedmaterial,
Food and Drug Administration 510(k) approved. Under this project,
preclinical studies were conducted to analyse the safety and efﬁ-
cacy of its association with MSC, including implantation in critical
size defects [9] The in vivo experiments conﬁrmed high coloniza-
tion of the biomaterial by osteogenic cells [10] The association of
BCP and BM-MSC did not affect MSC properties, in terms of im-
mune effector cell proliferation, immune effector cells viability, and
differentiation into osteoblast-like cells, suggesting that it could be
used in bone defects treatment instead of bone allograft or auto-
graft [11] Studies also showed that a minimum dose of cells of
10 106 per biomaterial cubic centimeter (cc) induced bone for-
mation [12] Ectopic bone formationwas observed under the skin of
nude mice using a combined dose of 20 million hMSC per 1 cc of
MBCP þ granules [13] Mixing MSC with the biomaterial and
allowing them to attach on its surface for 60min consistently
improved osteoinduction, if compared with isolated MSC [9].
The dose of BM-hMSC was strategically decided at 20 million
BM-hMSC as per experimental studies. In view of the potentially
variable requirements of biomaterial to ﬁll the bone defect, the
clinical protocol included a range of 100e200 million BM-hMSC to
be supplied to the clinical centre and combined with 5e10 cc of BCP
(1 or 2 syringes of biomaterial to combine with 1 or 2 syringes of
expanded cells containing 100 million BM-hMSC each) (see Fig. 2).
This combination could regenerate a critical size bone defect in
the skull of nude mice after 4 weeks [14] and could contribute to
healing a critical size defect in long bone of nude rats after 8 and 16
weeks [9].
MSC biodistribution is also a major safety concern for clinical
trials. Preclinical studies including qPCR for human Alu sequences
proved absence of unwanted MSC homing after IV infusion [15]
Subcutaneous implantation of MSCs with the scaffold showed no
recirculation or homing in other organs. Moreover, histological
analysis of different organs did not show any tumour formation
[16].
In such context, this multicentric clinical trial was designedwith
safety as the primary endpoint, based on preclinical ﬁndings. Safety
was evaluated as (1) local complication regarding the non-union
treatment in the follow-up (FU) and (2) local and general compli-
cation in the 12 month FU of patients regarding potential effects of
introducing the autologous hBM-MSC combined with BCP. A sec-
ondary endpoint was to prove the feasibility of fabricating MSCs
using a single standardized protocol across multiple institutions. A
tertiary endpoint was to get an estimate of the clinical efﬁcacy that
may be achieved using the combination of MSCs and this BCP
scaffold, to enable powering of future studies. Clinical efﬁcacy was
estimated by the proportion of patients with proven bone healing
(deﬁned as 3 cortices with bone bridging out of 4, conﬁrmed by
imaging) at 3, 6 and 12 months FU.nd safety of treating non-unions in tibia, femur and humerus with
lls associated with biphasic calcium phosphate biomaterials in a
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Table 1
Inclusion/Exclusion criteria.
No. Description
Inclusion criteria
1. Age 18 to 65
2. Both sexes (and efforts were placed to recruit females, if conﬁrmation of negative pregnancy test was obtained the day before surgery and birth control
methods were in place in case of fertile female patients)
3. traumatic isolated closed or open humerus, tibia, or femur diaphyseal or metaphysodiaphyseal fracture status delayed union or non-union at least 3
months from acute fracture
4. Signed informed consent
5. Being able to provide the consent
6. Able to understand and accept the study constraints
7. Medical health care coverage, in any of the participating countries.
Exclusion criteria
1. Pregnancy, breast feeding women and women who are of childbearing age and not practicing adequate birth control
2. Participation in another therapeutic trial in the previous 3 months
3. Delayed union or non-union related to iatrogeny
4. Segmental bone loss requiring speciﬁc therapy (like bone transport, large structural allograft, megaprosthesis, etc)
5. Persisting vascular or neural injury
6. Other fractures causing interference with weight bearing
7. Acute persistent chronic bacterial infections such as brucellosis, typhus, leprosy, relapsing fever, meliodosis and tularemia
8. Visceral injuries of diseases interfering with callus formation (craneoencephalic trauma, etc.)
9. History of bone harvesting on iliac crest contraindicating bone-marrow aspiration
10. Corticoid or immunosuppressive therapy more than one week in the three months prior to study inclusion
11. History of prior or concurrent diagnosis of HIV-, Syphilis, Hepatitis-B- or Hepatitis-C-infection (conﬁrmed by serology or PCR)
12. History of neoplasia or current neoplasia in any organ
13. Subject legally protected, under legal guardianship, deprived of their liberty by judicial or administrative decision, subject of psychiatric care, or
admission to a health facility
14. Impossibility to meet at the appointments for the follow up
15. Insulin dependent diabetes
16. Obesity (BMI > 30)
17. Autoimmune inﬂammatory disease, current treatment by biphosphonate or stopped in the three months prior to study inclusion.
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2.1. Study design and participants
ORTHO-1 was a phase I/IIa open, prospective, multicentric, non-
comparative interventional clinical trial from the REBORNE EU-
funded project (Regenerating Bone defects using New biomedical
Engineering approaches, FP7 HEALTH-2009-1.4-2, Grant Agreement
241879) designed to evaluate safety and feasibility of autologous
expanded Mesenchymal Stromal Cells (MSCs) from Bone Marrow
(BM) associated to a bioceramic (MBCP þ™) in patients with long
bone delayed unions and non-unions (after a minimum of 3
months from acute fracture). Inclusion and exclusion criteria for
patient selection are listed in Table 1.
This was performed in ﬁve European centres from four coun-
tries, with total recruitment of 30 patients, 28 of whom received
treatment (Fig. 1, CONSORT diagram) from March 2013 to February
2015.
During enrolment, the anonymous clinical data and imaging of
the eligible patient were forwarded to the other clinical centres.
Each patient was only included if no centre was against inclusion
and at least two more centres agreed on the inclusion and the
treatment. Enrolment of the ﬁrst four patients was staggered with a
minimum interval of two weeks after treatment of the previous
patient, to identify any potential early safety problems that may
have required terminating the trial. To further standardize the in-
clusion, patients to be included were those that alternatively would
have received bone autograft and/or BMP, thus excluding patients
with segmental defects.
Of the 30 recruited patients, one was excluded before bone
marrow extraction as hepatitis B virus positive serology was
conﬁrmed. A second one was excluded because bone healing was
identiﬁed before implantation surgery.
Of the 28 patients receiving treatment and analysed under ITT
(intention-to-treat), two of them caused early drop-out (one at
three months by patient decision, and the second at six months byPlease cite this article in press as: E. Gomez-Barrena, et al., Feasibility a
autologous, expanded, bone marrow-derived mesenchymal stromal ce
multicentric, non-comparative trial, Biomaterials (2018), https://doi.org/1surgeon decision and further treatment). In the remaining 26 pa-
tients, three cases showed protocol deviations (one required a
second bone marrow extraction due to insufﬁcient cell material in
the ﬁrst extraction; one required a second bone marrow extraction
due to false positive Mycoplasma testing in the cell product in the
ﬁrst expansion; in the third, an oropharyngeal carcinoma was
detected at intubation before cell implantation, the patient still
receiving the previously cultured cells and followed until six
months only due to exitus related to his cancer, ten months after
implantation). Two out of 28 cases received 100 million cells in 5 cc
of BCP, while 26 received the higher dose of 200 million cells in
10 cc of the biomaterial.
The treatment was performed at mean (range) 27.9 (3.9e163.3)
months after the initial fracture and 14.7 (2.1e36.0) months after
any previous treatment. Bone injuries that received treatment were
located in the femur (11/28), humerus (4/28), and tibia (13/28). The
initial fracture was closed in 17/28, and open fractures were seen in
11/28. Most common location was the distal third of the diaphysis
(11/28), followed by the middle diaphyseal third (10/28). Fracture
characteristics are further displayed in Table 2.
Safety analysis was planned for 12 months with intermediate
evaluations at three and six months. A total of 28 patients were
evaluated at three months, 27 at six months, and 25 patients were
available for the ﬁnal evaluation at 12 months on ITT.3. Ethical issues
Four Ethics Committees of clinical research (CPP Tours Region
Centre Ouest 1, Tours, France; La Paz Hospital CEIC, Madrid, Spain;
Ulm University EC, Ulm, Germany; and Istituto Ortopedico Rizzoli
EC, Bologna, Italy) approved the protocol and related documents for
all participating clinical centres. As the investigational medicinal
product (IMP) was an advanced therapy medicinal product (ATMP)
for human use, the ﬁnal responsibility to authorize the trial was set
at the National Competent Authorities (ANSM, France; AEMPS,
Spain; PEI, Germany; AIFA, Italy) as per Directive 2001/20/EC andnd safety of treating non-unions in tibia, femur and humerus with
lls associated with biphasic calcium phosphate biomaterials in a
0.1016/j.biomaterials.2018.03.033
Fig. 1. CONSORT diagram of ORTHO1 clinical trial.
E. Gomez-Barrena et al. / Biomaterials xxx (2018) 1e942005/28/EC of the European Parliament. The authorizations were
obtained in all participating countries between January and March
2013. The sponsor of the study was INSERM, Paris, France. The
EudraCT ﬁnal number of the trial was 2011-005441-13 (in France,
ID RCB number 2011-A00797-34), and the trial was also incorpo-
rated to the database ClinicalTrials.gov with the identiﬁer
NCT01842477.
4. Procedures
4.1. Bone marrow harvesting
Donation, procurement and testing of the BM were performed
in compliance with the European Cells and Tissues Directives; inPlease cite this article in press as: E. Gomez-Barrena, et al., Feasibility a
autologous, expanded, bone marrow-derived mesenchymal stromal ce
multicentric, non-comparative trial, Biomaterials (2018), https://doi.org/particular, according to the requirements laid down in Directive
2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC
of the European Parliament and of the European Council as regards
certain technical requirements for the donation, procurement and
testing of human tissues and cells, and applicable national laws.
Speciﬁcally, patients needed to be negative in serology for Anti-HIV
1-2 Ab, Anti-HCV Ab, HBs Ag, Anti-HBc Syphilis, and negative (not
detected by PCR) in HIV NAT, HCV NAT, or HBV NAT. The bone
marrow cells were harvested in an operating room under anes-
thesia, with a trocar by cutaneous puncture from the posterior iliac
crest. Bone marrow was harvested by fractions of 2e4ml in 20ml
syringes heparinized to avoid clotting, then transferred into a bag
for transportation preﬁlled with 5mL of heparin (1000 IU/ml), and
labeled according to the approved protocol. The harvest, in itsnd safety of treating non-unions in tibia, femur and humerus with
lls associated with biphasic calcium phosphate biomaterials in a
10.1016/j.biomaterials.2018.03.033
Table 2
Fracture characteristics of ORTHO-1 patients.
Variables ALL LONG BONES
n¼ 28
n (%)
Open/closed fracture
Clean wound, wound <1 cm in length (Gustilo 1) 6 (21.4%)
Wound >1 cm in length w/o extensive
soft-tissue damage (incl. ﬂaps)
(Gustilo more than 1)
5 (17.9%)
Closed fractures 17 (60.7%)
Fracture site
Proximal metaphysis or metaphyso-diaphysis 1 (3.6%)
Diaphyseal proximal third 4 (14.3%)
Diaphyseal middle third 10 (35.7%)
Diaphyseal distal third 11 (39.3%)
Distal metaphysis of metaphyso-diaphysis 2 (7.1%)
Bone loss/gap
No 17 (60.7%)
Yes, <50% diaph. Diam 7 (25.0%)
Yes, >50% diaph. Diam 4 (14.3%)
AO diaphyseal fracture classiﬁcation 25 (80.3%)
A. Simple 6 (21.4%)
A1. Spiral 1 (3.6%)
A2. Oblique >30 1 (3.6%)
A3. Transverse 4 (14.3%)
B. Wedge 9 (32.1%)
B1. Spiral 1 (3.6%)
B2. Bending wedge 5 (17.9%)
B3. Fragmented w/corner 3 (10.7%)
C. Complex 10 (35.7%)
C1. Spiral 2 (7.1%)
C2. Segmental 2 (7.1%)
C3. Irregular 6 (21.4%)
AO metaphyseal fracture classiﬁcation 3 (10.7%)
A. Simple
A1. Simple 1 (3.6%)
A2. Wedge 0 (0%)
A3. Complex 2 (7.1%)
Complex fracture 0 (0%)
E. Gomez-Barrena et al. / Biomaterials xxx (2018) 1e9 5primary packaging, was laid out in an isothermal box labeled ac-
c'ording to Directive 2004/23/EC and 2006/17/EC. The transport
was done under controlled temperature between 18 and 24 C if
less than 30min, and at 4 C with temperature traceability if the
transportation time was longer than 30min.4.2. Cell product manufacturing process in GMP facilities
The Investigational Medicinal Product (IMP) was composed of
human mesenchymal stromal cells from the bone marrow, ob-
tained through a manufacturing process based on plastic adher-
ence, and expanded in culture according to a culture method
developed by the REBORNE consortium using 5% human donor
platelet lysate produced in Ulm (Germany) and distributed to the
other cell therapy units. MSC were deﬁned by a speciﬁc immuno-
phenotype expressing the markers CD90, CD73, CD105 and nega-
tive for CD14, CD45 and HLA-DR [17] with demonstrated osteogenic
properties in vitro and in vivo. The IMPmanufacturing authorization
was granted to all ﬁve participating GMP facilities (Etablissement
Français du Sang eEFS- in Toulouse and in Creteil, both in France;
Transfusion Medicine Institute of Ulm in Germany; Fondazione
IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milano in Italy;
and Cell Production Unit at Hospital Puerta de Hierro-Majadahonda
of Madrid in Spain).
An aliquot of starting material was removed to carry out con-
trols including cell count, viability, CFU-F-assay, and sterility. The
entire manufacturing process was performed in each
manufacturing site, after previous validation in all sites with 22Please cite this article in press as: E. Gomez-Barrena, et al., Feasibility a
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multicentric, non-comparative trial, Biomaterials (2018), https://doi.org/1validation runs conﬁrming the compliance of all the validation
batches to the pre-deﬁned speciﬁcations. In brief, the culture was
performed when the received BM, without any further manipula-
tion, was seeded in alpha-MEM medium with 5% PL and 1U/mL of
heparin, at the concentration of 50.000 WBC/cm2, in a culture
chamber. The culture chambers were placed in incubators (5% CO2,
20% oxygen atmosphere, 95% relative humidity at 37 C). After 72 h,
the supernatant was discarded and replaced by fresh complete
medium (alpha-MEM with 5% PL). At days þ7 and þ 10 of culture,
the supernatant was discarded and replaced by complete medium.
At þ14 day, the conﬂuence was evaluated and, if >50%, the cells
were washed with PBS detached and harvested using trypsin
(TrypZean solution from recombinant corn e free of animal
componente at a concentration of 1, incubation time from 5 to
10 min). If cell conﬂuence was lower than 50%, an additional me-
dium exchange was performed and cells were harvested at day 17.
The harvested cells were then re-seeded at the concentration of
4  103 MSC per cm2 in new culture chambers in alpha-MEM
medium with 8% PL. Another medium exchange was performed
at day 17. At day 21, the cell culture was washed with PBS and the
cells detached and harvested using trypsin. The ﬁnal product
resulting in a dose of 20 106 cells per mL was suspended in 5%
human albumin up to 10mL to obtain the ORTHO-1 BMMSC tissue-
engineered product. The ﬁnal active product was packaged for the
shipment to the operating room (the delivery contained one or two
syringes of 5mL each). A suitable mode of transportation ensured
delivery of the package of BM to the manufacturing site and the
expanded cells from the GMP facility to the surgical room within
18 h, and the process was validated for cell viability [10,12].
Each batch of the ﬁnal product was tested for cell content,
immunophenotype, sterility, endotoxins and Mycoplasm before
release. Additional quality controls were performed according to
each country speciﬁc national competent requests.
All the materials and reagents were selected and validated to
ascertain their compliance to be used in themanufacturing process,
with certiﬁcates of analysis of key components included in the IMP
for which approval was obtained at each of the National Competent
Authorities (NCA) of the participating countries.
4.3. Biomaterial and cell product associated during surgery
The selected calcium phosphate biomaterial (MBCPþ, Bio-
matlante SA, Vigneux de Bretagne, France) was a 100% synthetic
CE-marked, FDA (510 k) approved bone substitute, composed of
20% Hydroxyapatite (HA) and 80% beta tricalciumphosphate (b-
TCP), in 1e2 mm granules. The material had a total porosity of 73%,
constituted of macropores (>100 mm), mesopores of 10e100 mm
andmicropores (<10 mm) content of about 40%. The crystal size was
<0.5e1 mm with a speciﬁc surface area around 6 m2/g. The cell-
biomaterial association was performed in the surgical room
before implantation (Fig. 2).
Standard operating procedure for mixing autologous MSCs and
MBCP þ ™ granules in the operating room during surgery. a) Sy-
ringes of expanded cells and biomaterial in the surgical setting. b)
Combination of both, before implantation.
Preclinical studies with BM-MSC at a concentration of 20 106
MSC/mL seeded on 1 cc of MBCP þ granules conﬁrmed that less
than 5% cells remained in the supernatant or attached to the
container after 60 min, and that cells on the BCP granules were
capable of forming bone [12].
Microscopy with crystal violet corroborated that cells were
attached to the biomaterial [10] within 60min, and live/dead assay
indicated that MSCs were alive on the biomaterial with very few
dead cells (Fig. 3a), showing uniform distribution of high cell
density on the granules with methylene blue staining (Fig. 3b).nd safety of treating non-unions in tibia, femur and humerus with
lls associated with biphasic calcium phosphate biomaterials in a
0.1016/j.biomaterials.2018.03.033
Fig. 2.
E. Gomez-Barrena et al. / Biomaterials xxx (2018) 1e96Surgical procedure and cell implantation, showing a) attach-
ment of MSCs on the biomaterial after 1 h as prepared in the sur-
gical room (methylene blue staining, magniﬁcation100, scale bar:
500 mm); b) Viability of MSC on BCP granules after 1 h (live/dead
assay, ﬂuorescence microscopy magniﬁcation 50, scale bar:
500 mm; Per protocol, cells were associated to the biomaterial
during surgery. Each 5mL of cell product syringe (cell dose of
20 106/mL) was mixed with 5 cc of biomaterial.
4.4. Surgical procedure
The non-union site was surgically prepared through a standard
surgical approach adapted to the anatomic location to receive the
biomaterial and cell product. This preparation included ablation of
necrotic free bone fragments, excision of ﬁbrous tissue and/or
decortication of bone ends to bleeding bone. The cell-biomaterial
combination product had a pasty consistency and was spread to
the full extent of the prepared volume.
5. Outcomes
5.1. Safety
To clinically conﬁrm the preclinical safety studies that observed
absence of toxicity or dissemination or histopathological detection
of any human tumour development (GLP preclinical study number
110068 from Oncodesign, Dijon, France), a primary safety end-
point, deﬁned as detection of local and general complications,
was ﬁxed for the clinical trial. This end-point was set at any time in
the 12 months of follow-up, but speciﬁcally required staggering the
ﬁrst four patients by two weeks, adverse event (AE) reporting at
three, six, and 12 months, severe adverse event (SAE) and sus-
pected unexpected and serious adverse reactions (SUSAR) report-
ing at any time, as required by the regulatory frame (to
Eudravigilance - European Union Pharmacovigilance database-, toFig. 3.
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identiﬁcation and report of each AE, SAE and SUSAR was made by
the physicians/researchers in each clinical centre coordinated by an
external Clinical Research Organization who was responsible of
monitoring the recorded data into the CRF and to release the ﬁnal
database. The assessment was conducted by the consortium clinical
trial research group.
5.2. Feasibility and early efﬁcacy
Feasibility was assessed in treatment preparation (BM harvest,
cell expansion and delivery to the surgical room) and administra-
tion (combination with the biomaterial and implantation) in a
multicentric international setting (both for cell production and
implantation).
Early efﬁcacy was clinically and radiologically evaluated at 3, 6
and 12 months follow-up (X-Rays and CT imaging was performed
per protocol during the FU of the clinical trial). Clinical efﬁcacy (Yes/
No) was considered when all the three following criteria were met:
Radiological bone bridging in 3 out of 4 cortices, on at least¾ views;
pain less than 3 (Likert scale from 0 to 10); no further surgical
intervention in the callus site (as nail or plate replacement, or
replacement of all components of the previous surgery). The
radiological bone bridgingwas assessed by an external adjudication
committee using blinded images.
6. Histology
Two of the cases requiring secondary surgical procedure (screw
extraction in locked nails) provided bone biopsies from the non-
union site about four months (111 days) and about eight months
(309 days) after cell product implantation. Bone cylinders were
percutaneously obtained under ﬂuoroscopy at the time of sec-
ondary surgery. These bone biopsies were ﬁxed in formaldehyde
10% and processed for decalciﬁed histology as previously describednd safety of treating non-unions in tibia, femur and humerus with
lls associated with biphasic calcium phosphate biomaterials in a
10.1016/j.biomaterials.2018.03.033
Table 3
ORTHO-1 adverse events.
Patient id FU days Description of the Adverse Event (AE) Severity Status* IMP relationship AE treated Duration (days) Outcome*
502 -27 Fever after BM aspiration Mild Ceased Deﬁnitely not No 5 Recovered
201 0 Ophthalmic migraine Mild Ceased Deﬁnitely not No 0 Recovered
401 8 Bacterial tonsillitis Moderate Ceased Deﬁnitely not Yes 5 Recovered
103 17 Superﬁcial infection related to musculocutaneous
vascularized ﬂapin surgical wound **
Mild Ceased Deﬁnitely not Yes 17 Recovered
404 31 Common cold Mild Ceased Deﬁnitely not Yes 7 Recovered
502 34 Superﬁcial infection of wound at the operation site Moderate Ceased Deﬁnitely not No 7 Recovered
402 42 Fatigue failure of implant** Severe Ceased Deﬁnitely not Yes 2 Recovered
104 56 Superﬁcial infection related to musculocutaneous
vascularized ﬂapin surgical wound **
Mild Ceased Deﬁnitely not Yes 7 Recovered
201 77 Rhinitis Mild Ceased Deﬁnitely not Yes 7 Recovered
401 82 Allergic reaction to unknown component Severe Ceased Probably not Yes 1 Recovered
104 94 Superﬁcial infection related to musculocutaneous
vascularized ﬂapin surgical wound
Mild Ceased Deﬁnitely not Yes 68 Recovered
101 100 Tendinitis in affected leg Moderate Ceased Deﬁnitely not Yes 11 Recovered
101 108 Inﬂuenza Mild Ceased Deﬁnitely not Yes 9 Recovered
105 111 Intervention to change distal locking screws Mild Ceased Deﬁnitely not Yes 1 Recovered
206 117 Foot numbed Mild Ceased Probably not No 7 Recovered
404 143 Bacterial sinusitis Moderate Ceased Deﬁnitely not Yes 38 Recovered
404 143 Trigeminal neuralgia Moderate Ceased Deﬁnitely not Yes 38 Recovered
402 157 Breakage of proximal locking screw Moderate Ceased Deﬁnitely not No 4 Recovered
203 176 Keratoseseborrheique Mild Ceased Deﬁnitely not No 0 Recovered
406 188 Gastric bleeding** Moderate Ceased Deﬁnitely not Yes 4 Recovered
201 302 Diarrhea Mild Ceased Deﬁnitely not Yes 4 Recovered
103 309 Intervention to remove proximal screw nail dynamization Mild Ceased Deﬁnitely not Yes 1 Recovered
201 335 Vertigo Mild Ceased Deﬁnitely not Yes 2 Recovered
IMP: Investigational medicinal product
*Status/Outcome at the end of the study; **Serious adverse event properly reported (Requiring in-patient hospitalization).
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Masson trichrome. Immunohistology was performed to identify
macrophages with human CD68 primary antibody (mouse anti-
human, 1/100, MCA1815T, AbdSerotec, Oxford, UK), revealed by
secondary antibody (goat anti-mouse biotinylated, 1/400, E0433,
Dako, Les Ulis, France), counterstained using Gill's hematoxylin
solution and covered with cover slips. Sections were viewed using
the Nanozoomer 2.0 Hamamatsu slide scanner (NanoZoomer;
Hamamatsu, Photonics, Hamamatsu City, Shizuoka Prefecture,
Japan).
7. Statistical analysis
Descriptive statistics were performed using STATA software
version 12 (StataCorp. 2011).
8. Role of funding source
Institutional public funding obtained in a competitive European
Union public call sustained all preclinical and clinical research. The
funding source did not inﬂuence any of the results or had any re-
sponsibility in the study design, collection, analysis, and interpre-
tation of data; in the writing of the report; or in the decision to
submit the paper for publication. The corresponding author con-
ﬁrms that he had full access to all the data in the study and had ﬁnal
responsibility for the decision to submit for publication.
9. Results
9.1. Safety
No adverse event, or SAE, or SUSAR, were identiﬁed in rela-
tionship with the IMP. Particularly, no tumorous condition or cell-
related overgrowth was detected in any patient after cell
implantation.
A total of 19 adverse events (AE) were reported (Table 3), 15 of
them were considered mild to moderate (fever, ophtalmicPlease cite this article in press as: E. Gomez-Barrena, et al., Feasibility a
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ﬂu, trigeminal neuralgia, vertigo, diarrhea, breakage of locking
screws requiring screw change, screw removal, tendinitis, residual
valgus knee deformity). A total of four severe adverse events were
reported requiring hospitalization, also with full recovery (Ap-
pendix). These included superﬁcial infection of the wound in two
patients that previously had musculocutaneous vascularized ﬂaps
in previous surgeries to treat the initial fracture, leaving a severe
atrophic scar and a compromised skin in the surgical approach.
Both required hospitalization to undergo intravenous antibiotic
treatment and both fully resolved without sinus tract, drainage or
surgical intervention into the non-union site. Apparently unrelated
gastric bleeding occurred in a patient 188 days after surgery who
fully recovered four days after hospital admittance. Finally, one
patient required intramedullary nail exchange (without opening
the fracture site) due to fatigue failure of the implant, 42 days after
cell implantation in which no nail modiﬁcation was originally
performed (the nail was apparently stable although in place for the
previous seven months).
Bone biopsies after histopathological evaluation conﬁrmed bone
formation surrounding the BCP granules with the attached,
expanded MSCs delivered into the non-union site at surgery.
Lamellar bone and osteoid tissues were found at the vicinity of
the BCP granules. Multinucleated giant cells labeled by the anti-
body CD68 and TRAP staining were primarily located surrounding
the BCP biomaterial. These cells were considered osteoclasts with a
pivotal role in bone regeneration, as demonstrated in preclinical
studies [13,18].9.2. Feasibility and early efﬁcacy
After appropriate protocol validation in all the participating
production centres, multinational authorization was obtained. This
fact reinforces the feasibility of autologous cell expansion as a
viable clinical, large-scale option. Descriptive cell values, along the
process of expansion and at release of the cell product in the treated
cases, are included in Table 4.nd safety of treating non-unions in tibia, femur and humerus with
lls associated with biphasic calcium phosphate biomaterials in a
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Table 4
Cell expansion and ﬁnal cell product.
Variables Mean± n/N SD (%) (Min- Max)
BM aspiration
Aspirated bone marrow volume 50.4 ± 18.6 (22.5- 90.0)
WBC concentration (x106/mL) 26.1 ± 11.3 (11.2- 61.0)
Seeded
No. of 2-chamber Cell stack layer seeded 3.5± 1.7 (2.0- 7.0)
Total volume of seeded BM (mL) 9.7 ± 5.3 (2.6 - 23.8)
Total No. seeded WBC (x106) 221.6 ± 106.1 (127.0 - 445.2)
Viability of starting material (%) 96.5 ± 2.9 (87.2e 100)
Clonogenicity: (CFUeF/106 MSC seeded) 47.0± 33.0 (4.0e 122.0)
Microbialtesting (No Growth) 28/28 (100%)
Reseeded at P0
Culture duration ofp0 (days) 13.6 ± 1.1 (10.0- 15.0)
No. of harvested MSC (x106) 161.1 ± 136.6 (16.8- 500.0)
Viability (%) 95.8 ± 4.4 (80.2- 100.0)
Clonogenicity: (x103 CFU-F/106 MSC seeded) 198.4± 140.0 (0.0- 500.0)
No. 2-chamber cell stack seeded 5.7± 1.7 (3.0- 8.0)
Microbial testing at P0 (No Growth) 28/28 (100%)
Reseeded at P1
Culture duration of p1 (days) 6.7 ± 0.8 (5.0- 9.0)
No. of MSC harvested (x106) 352.7 ± 128.9 (95.2- 690.0)
Viability (%) 97.5 ± 2.3 (91.8 - 100.0)
Clonogenicity: (x103 CFU-F/106 MSC seeded) 162.3± 158.8 (2.0- 500.0)
Microbial testing at P1(No Growth) 28/28 (100%)
Additional Quality control data
Flow cytometry:
Acquisition of CD3 performed (n¼ 13) 0.0 ± 0.1 (-0.3 - 0.4)
Acquisition of MHC class I performed (n¼ 19) 98.1 ± 3.6 (85.7- 100.0)
Karyotyping performed w/Findings 0/22 (0%) e
Mycoplasma screening w/Findings 0/22 (0%) e
Endotoxin test performed 0/19 (0%) e
MSC production release criteria
CD90þ (%) 99.1 ± 1.6 (92.2 - 100.0)
CD73þ (%) 97.9 ± 2.8 (89.9 - 100.0)
CD105þ (%) 97.6 ± 2.6 (86.7 - 99.9)
CD45þ (%) 0.1 ± 0.1 (0.0 - 0.5)
HLA DR (%) 0.8 ± 1.4 (0.0 - 6.0)
Viability (%) 97.5 ± 2.3 (91.8 - 100.0)
E. Gomez-Barrena et al. / Biomaterials xxx (2018) 1e98Treatment preparation and delivery was successfully performed
in 28 patients from 4 countries, 5 GMP cell production centres and
5 clinical centres, and this conﬁrms the feasibility of the treatment
application in different settings. Following the deﬁnition of radio-
logical bone healing (bridging of 3 out of 4 cortices), 26/28 (92%) of
the treated bone injuries were considered consolidated at 12
months post-implantation surgery.
9. Discussion
First accomplishment in this trial included the set-up of iden-
tical GMP fabrication procedure at 5 sites in four countries, with
strict release and safety screening criteria of culture expanded cells
that meet the deﬁnition of MSCs, together with a consortium of
treatment centres to deliver and evaluate treatment of long-bone
fracture non-unions. Second, this non-comparative trial achieved
fabrication and treatment delivery of 20 million BM-hMSC per mL
(100e200 million MSC in 5e10mL) in 28 attempts (two patients
needed to be re-aspirated, and the process repeated), conﬁrming
feasibility and demonstrating the absence of adverse events using a
total dose of cells (100e200 million MSC) that is higher than the
dose generally used in prior studies.
This high dose safely, successfully, and consistently obtained
clinical and radiological consolidation of femoral, tibial, and hu-
meral non-unions. The dose of MSCs provided to a site may be a
critical variable in the success of therapy. A relationship between
cell dose and clinical success has been previously proven in other
settings, such as the concentration of marrow derived nucleated
cells using density separation [19] This may also be the case with
expandedMSCs. The biological properties of the cells in a defect sitePlease cite this article in press as: E. Gomez-Barrena, et al., Feasibility a
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has shown that MSCs generated from cells harvested from a non-
union site, [20] have lower proliferative capability than MSCs that
are fabricated using cells harvested from native bone marrow [21]
The minimal required dose is currently unknown. Therefore, the
appropriate number of cells may require more studies. Current
uncertainty may justify the underreporting of results from many
registered clinical trials.
This study accomplished its primary and secondary goals of
demonstrating the feasibility and the safety of MSCs as a treatment
alternative for fracture non-union.
Feasibility was demonstrated by establishing a consortium for
multicentric production of MSCs using a common standard oper-
ating procedure (SOP) for generating a culture expanded MSC
product at ﬁve GMP facilities from four European countries. The
established SOP included rigorous safety screening for the end
product based on cell content, immunophenotype, sterility, endo-
toxins and karyotype. Based on intent to treat, MSCs were suc-
cessfully fabricated in 93% of patients on the ﬁrst attempt. Two
patients who failed in the initial fabrication were successfully
served by a second aspiration and fabrication procedure.
Safety was demonstrated in 28 patients, in whom no adverse
events could be attributed directly or indirectly to the use of MSCs
in their care.
While this studywas not designed as a test of clinical efﬁcacy, 26
of 28 patients demonstrated radiographic union during follow-up
(bridging 3 of 4 cortices). This represents a rate of clinical success
that is higher than most series of this type and severity, and pro-
vides reassurance that MSCs at the used dose (20 million cells per
1 cc of graft material) may provide therapeutic beneﬁt.nd safety of treating non-unions in tibia, femur and humerus with
lls associated with biphasic calcium phosphate biomaterials in a
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studies. The use of this dose was a strategic decision to minimize
the risk that the selected dose would be sub-therapeutic, while also
enhancing the strength of our safety assessment for MSCs. Prior
studies of the use of culture expanded MSCs have often been
equivocal in cell dose and outcomes, as previously reviewed [1,6].
The choice of a biphasic calcium phosphate ceramic was also
strategic.We believe thatmany biomaterials can successfully attach
cells and help to deliver them into the injury. We selected to
combine cells and material in the surgical room to isolate the cell
production technology issues from the potential biomaterial in-
ﬂuence in cell expansion. To play it safe, we selected a well-tested
biphasic ceramic in clinical use with proved cell attachment
properties and osteoconductive properties that are appropriate to
support a positive MSC effect on bone healing. Furthermore, we
used a particulate material to better adapt to the non-union gap. A
major future challenge for any biomaterial proposal combined with
ATMP would be to further undergo into comparative clinical trials,
to prove superiority about the current gold standard for bone
healing augmentation, such as bone autograft.
In conclusion, this study provided feasibility evidence of GMP,
multicentric, equivalent cell production of expanded BM-hMSC at a
dose up to 200 million cells. Furthermore, it proved multicentric
feasible and safe surgical delivery of this cell product in combina-
tion with 5e10 cc of BCP to treat long-bone fracture non-union,
without adverse events related to the cell product. Bone healing
obtained through this method and through a multicentric collab-
oration may help in the near future to compare the efﬁcacy of this
strategy with that of current clinical standards such as autograft, to
determine the appropriate cell dose, or to examine the relative
efﬁcacy of MSC delivery in alternative biomaterial scaffolds.
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